Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Bioorg Med Chem Lett ; 16(22): 5752-6, 2006 Nov 15.
Article in English | MEDLINE | ID: mdl-16950617

ABSTRACT

Introduction of selected amine containing side chains into the 3-position of N',2-diphenylquinoline-4-carbohydrazide based NK3 antagonists abolishes unwanted hPXR activation. Introduction of a fluorine at the 8-position is necessary to minimize unwanted hI(Kr) affinity and a piperazine N-tert-butyl group is necessary for metabolic stability. The lead compound (8m) occupies receptors within the CNS following oral dosing (Occ(90) 7 mg/kg po; plasma Occ(90) 0.4 microM) and has good selectivity and excellent PK properties.


Subject(s)
Fluorine/chemistry , Hydrazines/chemistry , Neurotransmitter Agents/pharmacology , Piperazines/chemistry , Quinolines/chemistry , Receptors, Neurokinin-3/antagonists & inhibitors , Administration, Oral , Animals , CHO Cells , Cricetinae , Dose-Response Relationship, Drug , Fluorine/pharmacology , Hydrazines/pharmacology , Piperazines/pharmacology , Quinolines/pharmacology , Structure-Activity Relationship , Tumor Cells, Cultured
2.
Bioorg Med Chem Lett ; 16(22): 5748-51, 2006 Nov 15.
Article in English | MEDLINE | ID: mdl-16950620

ABSTRACT

A new class of potent NK3R antagonists based on the N',2-diphenylquinoline-4-carbohydrazide core is described. In an ex vivo assay in gerbil, the lead compound 2g occupies receptors within the CNS following oral dosing (Occ(90) 30 mg/kg po; plasma Occ(90) 0.95 microM) and has good selectivity and promising PK properties.


Subject(s)
Hydrazines/chemistry , Hydrazines/pharmacology , Neurotransmitter Agents/chemistry , Neurotransmitter Agents/pharmacology , Quinolines/chemistry , Quinolines/pharmacology , Receptors, Neurokinin-3/antagonists & inhibitors , Administration, Oral , Animals , CHO Cells , Cricetinae , Dose-Response Relationship, Drug , Structure-Activity Relationship , Tumor Cells, Cultured
3.
J Med Chem ; 49(4): 1235-8, 2006 Feb 23.
Article in English | MEDLINE | ID: mdl-16480260

ABSTRACT

The identification of a series of imidazo[1,2-b][1,2,4]triazines with high affinity and functional selectivity for the GABA(A) alpha3-containing receptor subtype is described, leading to the identification of a clinical candidate, 11. Compound 11 shows good bioavailability and half-life in preclinical species, and it is a nonsedating anxiolytic in both rat and squirrel monkey behavioral models.


Subject(s)
Anti-Anxiety Agents/chemical synthesis , GABA-A Receptor Agonists , Imidazoles/chemical synthesis , Triazines/chemical synthesis , Animals , Anti-Anxiety Agents/chemistry , Anti-Anxiety Agents/pharmacology , Biological Availability , Half-Life , Humans , Imidazoles/chemistry , Imidazoles/pharmacology , Patch-Clamp Techniques , Radioligand Assay , Rats , Receptors, GABA-A/physiology , Saimiri , Structure-Activity Relationship , Triazines/chemistry , Triazines/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...